MapLight Therapeutics, Inc. (NASDAQ:MPLT) has seen insider activity from its executive leadership following a period of notable stock price appreciation. Erin Pennock Foff, the company's Chief Medical Officer, sold 4,438 shares of voting common stock on May 7, 2026, for a total value of $126,639. The sale was conducted via multiple transactions under a Rule 10b5-1 trading plan adopted by Ms. Foff in late December 2025.
Transaction Breakdown
The share disposal was segmented into two distinct parts:
- A primary block of 4,321 shares was sold at a weighted average price of $28.52 per share, with individual transaction prices ranging from $28.08 to $29.045.
- An additional 117 shares were transacted at a weighted average price of $29.10 per share, with individual prices between $29.09 and $29.10.
The total price range for the entire disposal fell between $28.52 and $29.1 per share. Despite these sales, Ms. Foff retains a substantial direct interest in the company, holding 346,059 shares of voting common stock.
Market Context and Valuation
The timing of this insider sale coincides with a period of aggressive growth for MPLT. The stock is currently trading around $30, which is in close proximity to its 52-week high of $33.28. This follows a substantial 108% surge in share price over the past six months. In the most recent week alone, the stock saw an increase of nearly 8%. Financial analysis suggests that the company's current trading price is slightly above its estimated Fair Value.
Clinical Pipeline and Analyst Sentiment
MapLight Therapeutics is currently navigating several critical milestones within its neuropsychiatric treatment pipeline. The company has recently reached two major clinical endpoints:
- Completion of enrollment for the Phase 2 ZEPHYR trial, which evaluates ML-007C-MA for the treatment of schizophrenia.
- The conclusion of the final patient visit in the Phase 2 IRIS trial, focused on ML-004 for autism spectrum disorder.
Management expects to provide topline results from both clinical trials by mid-August 2026. This upcoming data is a focal point for market analysts. TD Cowen has initiated coverage with a buy rating, specifically noting the potential of the central nervous system and neuropsychiatric pipeline assets, such as ML-007C-MA. Similarly, Stifel has maintained a Buy rating and a $28.00 price target. Stifel's assessment noted that the Phase 2 data for ML-007C-MA is expected in the third quarter of 2026. Analysts have highlighted that while the M1/M4 mechanism is considered de-risked by Cobenfy, investors are looking for evidence of efficacy and potential differentiation regarding safety, dosing, or tolerability.